Macquarie Group’s Capricor Therapeutics CAPR Stock Holding History

Macquarie Group’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-941	Closed	-$6	–	1938
2024 Q1	$6	Buy	+941	New	+$4.55K	﹤0.01%	1765

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Macquarie Group's CAPR Position: Q2 2024 in Review

Macquarie Group sold out of Capricor Therapeutics (CAPR) in Q2 2024, closing a stake of 941 shares — an estimated $6 sold.

Macquarie Group first reported a position in CAPR in Q1 2024 and held it in 1 quarter. The position peaked at $6 in Q1 2024. 61 funds tracked by Wall St. Rank hold CAPR as of Q2 2024.

Macquarie Group reported no remaining Capricor Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 941 Capricor Therapeutics shares in Q2 2024, an estimated $6.
Macquarie Group first reported a position in Capricor Therapeutics in Q1 2024 and held it in 1 quarter.
Macquarie Group's Capricor Therapeutics position peaked at $6 in Q1 2024.
61 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.